The September harvest is a time of great expectation—and great anxiety. For centuries, a community’s very survival depended on whether the fruits (and vegetables) of its labor could last a long, harsh winter. Today, HIVers are reaping a treatment harvest of their own. After a cruel dry spell, we have tipranavir (Aptivus)—the first truly new HIV med approved in more than a year—and are expecting a crop of at least three more in the year ahead. Indeed, for the first time in five years, the drug pipeline is ripe with antivirals—at least a dozen could hit your local pharmacy by 2010. While no cure, this bounty will likely buy much-needed health and time for thousands of HIVers and multiply treatment options for everyone.
A Trip to Bountiful
September 1, 2005 • By David Evans